MTM Drug Therapy Monitoring & Clinical Decision-Making 5 — Questions and Answers
Question 1: A patient with bipolar disorder on valproic acid has a level of 65 mcg/mL (therapeutic 50-125 mcg/mL) but still has breakthrough mania. What is the most appropriate clinical action?
- Add lithium as an adjunct therapy
- Increase valproic acid dose targeting 100-125 mcg/mL (Correct answer)
- Switch to carbamazepine monotherapy
- Add an antidepressant to the regimen
Correct answer: Increase valproic acid dose targeting 100-125 mcg/mL
Valproic acid level is suboptimal within the therapeutic range; increasing the dose to target the higher end (100-125 mcg/mL) is the appropriate first step before adding a second agent.
Question 2: Which assessment finding would prompt a pharmacist to recommend DECREASING the frequency of blood pressure monitoring from weekly to monthly in a stable hypertensive patient?
- Two consecutive readings below 120/80 mmHg
- Three consecutive readings at goal (130/80 mmHg) on stable therapy over 3 months (Correct answer)
- Patient reports no headaches for the past month
- No medication changes in the past 30 days
Correct answer: Three consecutive readings at goal (130/80 mmHg) on stable therapy over 3 months
Consistent at-goal blood pressure readings over multiple months on stable therapy indicate the patient is well-controlled, supporting a reduced monitoring frequency.
Question 3: A patient with HIV on a protease inhibitor-based regimen is started on inhaled fluticasone for asthma. Which adverse outcome should the pharmacist monitor for most urgently?
- Adrenal suppression and Cushing syndrome (Correct answer)
- Increased risk of opportunistic infections
- Reduced antiretroviral efficacy
- QT interval prolongation
Correct answer: Adrenal suppression and Cushing syndrome
Ritonavir (a common protease inhibitor booster) strongly inhibits CYP3A4, markedly increasing fluticasone systemic exposure and risking iatrogenic Cushing syndrome and adrenal suppression.
Question 4: When monitoring a patient on clozapine, which laboratory value requires the MOST stringent surveillance schedule due to a potentially fatal adverse effect?
- Fasting glucose (monthly for 3 months, then quarterly)
- Absolute neutrophil count (ANC) per REMS protocol (Correct answer)
- QTc interval (baseline and after each dose increase)
- Serum clozapine level (every 6 months)
Correct answer: Absolute neutrophil count (ANC) per REMS protocol
Clozapine's REMS program mandates ANC monitoring to detect clozapine-induced agranulocytosis, a potentially fatal adverse effect requiring immediate drug discontinuation if ANC falls below threshold.
Question 5: A 78-year-old patient on warfarin for atrial fibrillation has a CHA₂DS₂-VASc score of 5 and HAS-BLED score of 4. What is the most appropriate clinical recommendation?
- Discontinue warfarin due to bleeding risk outweighing stroke benefit
- Continue warfarin with frequent INR monitoring and address modifiable bleeding risk factors (Correct answer)
- Switch to aspirin 325 mg for safer stroke prevention
- Hold anticoagulation until bleeding risk factors are fully resolved
Correct answer: Continue warfarin with frequent INR monitoring and address modifiable bleeding risk factors
A high HAS-BLED score should prompt correction of modifiable bleeding risks (e.g., uncontrolled hypertension, interacting drugs), not anticoagulation discontinuation, as stroke risk remains substantially higher.
Question 6: Which clinical indicator best confirms therapeutic response to bisphosphonate therapy in a patient with osteoporosis after 2 years of treatment?
- Patient reports no falls in the past year
- Serum alkaline phosphatase levels decreased by 25-30%
- DEXA scan shows T-score improvement from -2.8 to -2.3 (Correct answer)
- Serum calcium remains within normal limits
Correct answer: DEXA scan shows T-score improvement from -2.8 to -2.3
Improvement in BMD T-score on DEXA scan is the primary objective measure of bisphosphonate efficacy, with a target of at least stable or improved scores after 2 years.
Question 7: A patient on clopidogrel post-PCI is also prescribed omeprazole for GI protection. Which clinical concern should guide the pharmacist's recommendation regarding this combination?
- Omeprazole increases clopidogrel absorption causing bleeding risk
- CYP2C19 inhibition by omeprazole may reduce clopidogrel's antiplatelet effect (Correct answer)
- Clopidogrel reduces omeprazole efficacy for acid suppression
- The combination is contraindicated per FDA black box warning
Correct answer: CYP2C19 inhibition by omeprazole may reduce clopidogrel's antiplatelet effect
Omeprazole inhibits CYP2C19, which is required to convert clopidogrel to its active metabolite, potentially reducing antiplatelet efficacy and increasing thrombotic risk post-PCI.
MTM Drug Therapy Monitoring & Clinical Decision-Making 5
A patient with bipolar disorder on valproic acid has a level of 65 mcg/mL (therapeutic 50-125 mcg/mL) but still has breakthrough mania.
What is the most appropriate clinical action?